The expression levels of Bcl-2 can have significant clinical implications. For instance, in follicular lymphoma, high levels of Bcl-2 are often associated with a poor prognosis. Conversely, targeting Bcl-2 with specific inhibitors like Venetoclax has shown promise in treating certain types of Bcl-2 overexpressing cancers.